米氮平与多虑平治疗躯体化障碍的对照研究

目的观察米氮平对躯体化障碍的疗效和副反应。方法将60例躯体化障碍患者随机分成米氮平组和多虑平组,治疗8周,用症状自评量表（SCL-90）,临床疗效大体评定量表（CG I）评定疗效,用副反应量表（TESS）评定副反应。结果治疗8周后,米氮平和多虑平组的疗效相当（2χ=0.869,P〉0.05）,在治疗第2周末米氮平组的SCL-90总分,躯体化、抑郁及焦虑均低于治疗前,且躯体化、抑郁和焦虑同多虑平组同期比较均降低（t=2.876~6.246,P〈0.05或P〈0.01）。结论米氮平治疗躯体化障碍疗效确切,起效快,副反应小,可作为躯体化障碍治疗的首选药物之一。

Controlled Study of Mintazapine and Doxepin in the Treatment of Somatization Disorder

Objective To assess the efficacy and side effects of mintazapine in treatment of somatization disorder. Methods A total of 60 patients with somatization disorder were randomly divided into two groups with mirtazapine or doxepin for 8 weeks. Symptom Checklist 90 （SCL-90）and clinical global impression（CGI）were used to assess the efficacy. Treatment emergent symptom scale（TESS）was used to assess side effects. Results After 8 weeks,Mintazapine and Doxepin had similar therapeutic efficacy （x^2= 0. 869 ,P〉0. 05） sAt the end of 2 weeks,treatment group＇ SCL-90 total score ,depression and anxiety were lower than before treatment,and somatization ,depression and anxiety compared with doxpin group were significantly reduced （t=2.876-6. 246, P〈0.05 or P〈0. 01） ,while Mintazapine showed efficacy earlier and had fewer side effects than Doxepin. Conclusion Mirtazapine is effective,rapid effect and fewer side effects,and can be used as a primary treatment of somatization disorder.